Improved overall survival in an anti‑PD‑L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial
Concurrent atezolizumab with radiation and temozolomide improves overall survival in newly diagnosed glioblastoma patients
This phase I/II trial aims to evaluate the efficacy of concurrent atezolizumab with radiation therapy and temozolomide (TMZ) followed by adjuvant atezolizumab and TMZ in newly diagnosed glioblastoma (GBM) patients and to identify pre‑treatment correlates with outcome (N = 60). Trial number: NCT03174197. The primary outcome was overall survival (OS) whereas secondary outcomes were retrospective global‑omics analyses to identify pre‑treatment immune and genetic tumor features that correlated with survival. Concurrent use of atezolizumab with radiation and TMZ demonstrated OS in line with published trials for newly diagnosed GBM.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma